Lu et al. reported that serum hepassocin concentrations are gradually increased in diabetic patients with NAFLD, and suggested that increased hepassocin levels might have clinical implications and could play a role as a biomarker for diabetes and NAFLD 25. The gene discussed is FGL1; the disease is metabolic dysfunction-associated steatotic liver disease.